Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 4Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Hematologic Neoplasms 3Leukemia 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Stomach Neoplasms 1Spondylitis, Ankylosing 1Solid Tumors 1Sarcoma, Kaposi 1Respiratory Tract Infections 1Respiratory Distress Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Nasopharyngeal Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Mesothelioma 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphohistiocytosis, Hemophagocytic 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1

Interventions

Ribavirin 2tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Respiratory Tract Infections × tocilizumab × Clear all
NCT04377659 2025-05-28

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
9 enrolled 8 charts

COVID-19, Respiratory Tract Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡